iothalamic acid and Cirrhosis

iothalamic acid has been researched along with Cirrhosis in 1 studies

Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.

Research

Studies (1)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Incidence of Acute Cellular Rejection

The primary purpose of this research study is to evaluate whether the use of mycophenolate mofetil/Cellcept ® and either tacrolimus/Prograf ® (Group #1) or mycophenolate mofetil/Cellcept ® and sirolimus/Rapamune® (Group #2) impacts the incidence of acute cellular rejection in post-kidney transplant patients. This study will examine whether switching from tacrolimus to sirolimus will better preserve long-term kidney function. (NCT00866879)
Timeframe: Assessed at 6 Months, 12 Months, 24 Months, months 24 reported

Percentage of Regulatory T Cells

"Specifically we reported here the percentage of regulatory T cells that were present in the two groups at 24 months post randomization.~With peripheral leukocytes taken at baseline (first visit) prior to randomization and at 6, 12 and 24 Months post-randomization, researchers will also review possible modifications of lymphocytes function and of the lymphocytes subpopulations that might have occurred as a consequence of the switch from tacrolimus to sirolimus (randomization)." (NCT00866879)
Timeframe: Assessed at 6 Months, 12 Months, 24 Months, months 24 reported

Renal Allograft Function Calculated With e-GFR and Proteinuria

Evaluate whether CI conversion (tacrolimus→sirolimus) contributes positively or negatively on the renal allograft function calculated with e-GFR and proteinuria (NCT00866879)
Timeframe: Assessed at 6 Months, 12 Months, 24 Months, months 24 reported

Evaluate if CI Conversion Impacts on Lipid Profile, Incidence of Hypertension, Malignancies, and Opportunistic Infections and Post-transplant DM

In addition to monitoring renal allograft function, evaluation will be conducted on the incidence of acute rejection, patient and graft survival, the impact of CI conversion on the lipid profile, the incidence of hypertension, malignancies, opportunistic infections and post-transplant DM (de novo diabetes mellitus). (NCT00866879)
Timeframe: Assessed at 6 Months, 12 Months, 24 Months, months 24 reported

Patient and Graft Survival

This study also reviews the impact of the immunosuppressive medications on patient and graft survival. (NCT00866879)
Timeframe: Assessed at 6 Months, 12 Months, 24 Months, months 24 reported

Trials

1 trial available for iothalamic acid and Cirrhosis